MedImmune has exercised an option to obtain an exclusive license to an antigen target under its antibody-drug conjugate (ADC) collaboration with Seattle Genetics, triggering a $1.5 million payment. This is the second target MedImmune has licensed through the agreement. Seattle Genetics and MedImmune entered into the ADC collaboration in April 2005 to provide MedImmune with access to Seattle Genetics’ ADC technology for antibodies targeting as many as two antigens. MedImmune paid an upfr...